Business Combinations and Asset Purchases (Tables)

12 Months Ended

Dec. 31, 2023

Business Acquisition, Pro Forma Information [Table Text Block]

The following unaudited pro forma information presents the combined financial results for the Company and BioLegend as if the acquisition of BioLegend had been completed at the beginning of fiscal year 2020:


	January 2, 2022
	(In thousands, except per share data)
Pro Forma Statement of Operations Information:
Revenue	$	4,056,122
Income from continuing operations	947,387
Basic earnings per share:
Income from continuing operations	$	7.27
Diluted earnings per share:
Income from continuing operations	$	7.25

Fair Values of the Business Combinations and Allocations for the Acquisitions Completed

The total purchase price for the acquisitions in fiscal year 2021 has been allocated to the estimated fair value of assets acquired and liabilities assumed as follows:


	Final
	BioLegend		Other
	(In thousands)
Fair value of business combinations:
Cash payments	$	3,336,115	$	1,128,584
Common stock issued	2,638,369		—
Other liability	6,857		2,910
Contingent consideration	—		45,031
Working capital and other adjustments	—		183
Less: cash acquired	(292,377)		(195,010)
Total	$	5,688,964	$	981,698
Identifiable assets acquired and liabilities assumed:
Current assets	$	184,704	$	71,840
Property, plant and equipment	147,200		26,507
Other assets	9,330		15,527
Identifiable intangible assets:
Core technology and clone library	782,400		290,089
Trade names and patents	38,000		39,476
Licenses	8,979		—
Customer relationships and backlog	1,714,800		141,670

Goodwill	3,509,931		545,262
Deferred taxes	(668,919)		(80,923)
Deferred revenue	—		(1,197)
Debt assumed	—		(4,628)
Liabilities assumed	(37,461)		(61,925)
Total	$	5,688,964	$	981,698